Merrion Investment Management’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$326K Hold
2,080
0.15% 95
2026
Q1
$318K Hold
2,080
0.17% 90
2025
Q4
$287K Sell
2,080
-120
-5% -$15.7K 0.15% 100
2025
Q3
$282K Sell
2,200
-170
-7% -$20.7K 0.16% 94
2025
Q2
$287K Hold
2,370
0.19% 88
2025
Q1
$264K Sell
2,370
-165
-7% -$17.6K 0.19% 88
2024
Q4
$247K Hold
2,535
0.17% 90
2024
Q3
$292K Hold
2,535
0.19% 85
2024
Q2
$270K Hold
2,535
0.19% 85
2024
Q1
$245K Hold
2,535
0.18% 90
2023
Q4
$256K Hold
2,535
0.2% 80
2023
Q3
$258K Sell
2,535
-865
-25% -$87.8K 0.22% 77
2023
Q2
$343K Hold
3,400
0.29% 66
2023
Q1
$313K Hold
3,400
0.3% 61
2022
Q4
$308K Sell
3,400
-350
-9% -$29.5K 0.29% 62
2022
Q3
$285K Hold
3,750
0.28% 66
2022
Q2
$317K Sell
3,750
-190
-5% -$16.7K 0.31% 64
2022
Q1
$345K Buy
3,940
+2
+0.1% +$173 0.25% 72
2021
Q4
$344K Hold
3,938
0.25% 73
2021
Q3
$322K Hold
3,938
0.25% 71
2021
Q2
$359K Sell
3,938
-110
-3% -$9.79K 0.27% 68
2021
Q1
$346K Buy
4,048
+1
+0% +$90 0.29% 63
2020
Q4
$382K Buy
+4,047
New +$354K 0.32% 59

Other funds holding NVS

Merrion Investment Management's NVS Position: Q2 2026 in Review

Merrion Investment Management held its Novartis (NVS) position steady in Q2 2026 at 2,080 shares worth $326K. The position accounts for 0.15% of the portfolio, ranked #95.

Merrion Investment Management first reported a position in NVS in Q4 2020 and has held it in 23 quarters since. The position peaked at $382K in Q4 2020. 734 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • Merrion Investment Management held 2,080 shares of Novartis worth $326K as of Q2 2026.
  • Merrion Investment Management left its Novartis share count unchanged in Q2 2026.
  • Novartis made up 0.15% of Merrion Investment Management's portfolio in Q2 2026, its #95 holding.
  • Merrion Investment Management first reported a position in Novartis in Q4 2020 and has held it in 23 quarters since.
  • Merrion Investment Management's Novartis position peaked at $382K in Q4 2020.
  • 734 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Merrion Investment Management's 13F filing for Q2 2026, filed 13 Jul 2026.